Related references
Note: Only part of the references are listed.Invasive Breast Cancer
Robert W. Carlson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation
L. de Plater et al.
BRITISH JOURNAL OF CANCER (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Patient-derived breast cancer xenografts: Molecular characteristics and growth properties
T. Giesemann et al.
EJC SUPPLEMENTS (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2010)
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Li Ding et al.
NATURE (2010)
Mammary Epithelial-Specific Ablation of the Focal Adhesion Kinase Suppresses Mammary Tumorigenesis by Affecting Mammary Cancer Stem/Progenitor Cells
Ming Luo et al.
CANCER RESEARCH (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Anna Bergamaschi et al.
MOLECULAR ONCOLOGY (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening
Lesley A. McLaughlin et al.
DRUG METABOLISM AND DISPOSITION (2008)
Short Preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
Marta Guix et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Of mice and (wo)men: Is this any way to test a new drug?
Tufia C. Haddad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A new model of patient tumor-derived breast cancer Xenografts for preclinical assays
Elisabetta Marangoni et al.
CLINICAL CANCER RESEARCH (2007)
Murine models to evaluate novel and conventional therapeutic strategies for cancer
James E. Talmadge et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Modelling breast cancer: one size does not fit all
Tracy Vargo-Gogola et al.
NATURE REVIEWS CANCER (2007)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve et al.
CANCER CELL (2006)
Identification of human cells in brain xenografts and in neural co-cultures of rat by in situ hybridisation with Alu probe
L Just et al.
JOURNAL OF NEUROSCIENCE METHODS (2003)
Calibration of immunohistochemistry for assessment of HER2 in breast cancer:: results of the French Multicentre GEFPICS Study
A Vincent-Salomon et al.
HISTOPATHOLOGY (2003)
Targeted disruption of the aromatase P450 gene (Cyp19) in mice and their ovarian and uterine responses to 17β-oestradiol
K Toda et al.
JOURNAL OF ENDOCRINOLOGY (2001)
High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma:: comparison with biochemical determination in a prospective study of 793 cases
B Zafrani et al.
HISTOPATHOLOGY (2000)
Share Paper
